Story perspectives

Viatris to Buy Pacira for $1.65 Billion Cash

By Drooid · Oct 8, 2026, 6:58 PM UTC · How we work

Summary

Story summary

Viatris announced a $1.65 billion cash acquisition of Pacira BioSciences.
The deal values Pacira at $36.50 per share, a 44.8% premium.
Pacira posted $746 million revenue, $177 million adjusted EBITDA, and 2025 sales of $575.1 million for Exparel and $116.6 million for Zilretta.
The acquisition is immediately accretive.
The FDA will rule on meloxicam by Dec. 27.

1 of 1

Story summary

Viatris announced a $1.65 billion cash acquisition of Pacira BioSciences.
The deal values Pacira at $36.50 per share, a 44.8% premium.
Pacira posted $746 million revenue, $177 million adjusted EBITDA, and 2025 sales of $575.1 million for Exparel and $116.6 million for Zilretta.
The acquisition is immediately accretive.
The FDA will rule on meloxicam by Dec. 27.